Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 692

1.

Discovery, synthesis and evaluation of oxynitidine derivatives as dual inhibitors of DNA topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1), and potential antitumor agents.

Zhang X, Wang HW, Tang WL, Zhang Y, Yang H, Hu DX, Ravji A, Marchand C, Kiselev E, Ofori-Atta K, Agama K, Pommier Y, An LK.

J Med Chem. 2018 Oct 18. doi: 10.1021/acs.jmedchem.8b00639. [Epub ahead of print]

PMID:
30336023
2.

Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.

Lee HS, Carmena M, Liskovykh M, Peat E, Kim JH, Oshimura M, Masumoto H, Teulade-Fichou MP, Pommier Y, Earnshaw WC, Larionov V, Kouprina N.

Cancer Res. 2018 Aug 30. pii: canres.0894.2018. doi: 10.1158/0008-5472.CAN-18-0894. [Epub ahead of print]

PMID:
30166419
3.

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.

Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD.

Mol Autism. 2018 Aug 17;9:45. doi: 10.1186/s13229-018-0228-2. eCollection 2018.

4.

TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining.

Kawale AS, Akopiants K, Valerie K, Ruis B, Hendrickson EA, Huang SN, Pommier Y, Povirk LF.

Nucleic Acids Res. 2018 Sep 28;46(17):8926-8939. doi: 10.1093/nar/gky694.

5.

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.

Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, Zhang YW, Giaccone G.

Oncogene. 2018 Aug 9. doi: 10.1038/s41388-018-0429-3. [Epub ahead of print]

PMID:
30093630
6.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1498. [Epub ahead of print]

PMID:
30061364
7.

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.

Zhao XZ, Métifiot M, Kiselev E, Kessl JJ, Maddali K, Marchand C, Kvaratskhelia M, Pommier Y, Burke TR Jr.

Molecules. 2018 Jul 26;23(8). pii: E1858. doi: 10.3390/molecules23081858.

8.

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y.

Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10.

PMID:
29748210
9.

Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3'- and 5'-phosphodiester-DNA bond cleavage.

Kiselev E, Dexheimer TS, Marchand C, Huang SN, Pommier Y.

DNA Repair (Amst). 2018 Jun - Jul;66-67:64-71. doi: 10.1016/j.dnarep.2018.05.001. Epub 2018 May 2.

PMID:
29747024
10.

ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S.

Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6.

11.

PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes.

Rehman I, Basu SM, Das SK, Bhattacharjee S, Ghosh A, Pommier Y, Das BB.

Nucleic Acids Res. 2018 Jun 20;46(11):5601-5617. doi: 10.1093/nar/gky291.

12.

Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2).

Yu LM, Hu Z, Chen Y, Ravji A, Lopez S, Plescia CB, Yu Q, Yang H, Abdelmalak M, Saha S, Agama K, Kiselev E, Marchand C, Pommier Y, An LK.

Eur J Med Chem. 2018 May 10;151:777-796. doi: 10.1016/j.ejmech.2018.04.024. Epub 2018 Apr 12.

PMID:
29677635
13.

The evolving landscape of predictive biomarkers of response to PARP inhibitors.

Thomas A, Murai J, Pommier Y.

J Clin Invest. 2018 May 1;128(5):1727-1730. doi: 10.1172/JCI120388. Epub 2018 Apr 16.

14.

New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Ribeiro CJA, Kankanala J, Shi K, Kurahashi K, Kiselev E, Ravji A, Pommier Y, Aihara H, Wang Z.

Eur J Pharm Sci. 2018 Jun 15;118:67-79. doi: 10.1016/j.ejps.2018.03.021. Epub 2018 Mar 21.

PMID:
29574079
15.

Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2S short isoform.

Huang SN, Dalla Rosa I, Michaels SA, Tulumello DV, Agama K, Khiati S, Jean SR, Baechler SA, Factor VM, Varma S, Murai J, Miller Jenkins LM, Kelley SO, Pommier Y.

EMBO Rep. 2018 Mar;19(3). pii: e42139. doi: 10.15252/embr.201642139. Epub 2018 Feb 9.

PMID:
29438979
16.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.

PMID:
29395061
17.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.

PMID:
29391350
18.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

PMID:
29252124
19.

ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K.

PLoS One. 2017 Nov 17;12(11):e0188320. doi: 10.1371/journal.pone.0188320. eCollection 2017.

20.

Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides.

Jun JH, Kumar V, Dexheimer TS, Wedlich I, Nicklaus MC, Pommier Y, Malhotra SV.

Eur J Pharm Sci. 2018 Jan 1;111:337-348. doi: 10.1016/j.ejps.2017.10.017. Epub 2017 Oct 13.

PMID:
29037996
21.

Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription.

Dalla Rosa I, Zhang H, Khiati S, Wu X, Pommier Y.

J Biol Chem. 2017 Dec 8;292(49):20162-20172. doi: 10.1074/jbc.M117.815241. Epub 2017 Oct 11.

PMID:
29021209
22.

HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia.

Takiuchi Y, Kobayashi M, Tada K, Iwai F, Sakurada M, Hirabayashi S, Nagata K, Shirakawa K, Shindo K, Yasunaga JI, Murakawa Y, Rajapakse V, Pommier Y, Matsuoka M, Takaori-Kondo A.

Sci Rep. 2017 Oct 9;7(1):12849. doi: 10.1038/s41598-017-12924-0.

23.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

24.

Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae.

Sloan R, Huang SN, Pommier Y, Jinks-Robertson S.

DNA Repair (Amst). 2017 Nov;59:69-75. doi: 10.1016/j.dnarep.2017.09.004. Epub 2017 Sep 18.

PMID:
28961461
25.

Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.

Zhang H, Seol Y, Agama K, Neuman KC, Pommier Y.

Sci Rep. 2017 Aug 17;7(1):8614. doi: 10.1038/s41598-017-09258-2.

26.

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.

Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.

PMID:
28802254
27.

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.

Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.

28.

Genome Organization Drives Chromosome Fragility.

Canela A, Maman Y, Jung S, Wong N, Callen E, Day A, Kieffer-Kwon KR, Pekowska A, Zhang H, Rao SSP, Huang SC, Mckinnon PJ, Aplan PD, Pommier Y, Aiden EL, Casellas R, Nussenzweig A.

Cell. 2017 Jul 27;170(3):507-521.e18. doi: 10.1016/j.cell.2017.06.034. Epub 2017 Jul 20.

29.

Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1).

Bermingham A, Price E, Marchand C, Chergui A, Naumova A, Whitson EL, Krumpe LRH, Goncharova EI, Evans JR, McKee TC, Henrich CJ, Pommier Y, O'Keefe BR.

SLAS Discov. 2017 Jul 1:2472555217717200. doi: 10.1177/2472555217717200. [Epub ahead of print]

PMID:
28697309
30.

Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Elsayed MSA, Su Y, Wang P, Sethi T, Agama K, Ravji A, Redon CE, Kiselev E, Horzmann KA, Freeman JL, Pommier Y, Cushman M.

J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.

PMID:
28657311
31.

DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

Reinhold WC, Thomas A, Pommier Y.

Trends Cancer. 2017 Jan;3(1):2-6. doi: 10.1016/j.trecan.2016.11.002.

32.

Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).

Wang P, Elsayed MSA, Plescia CB, Ravji A, Redon CE, Kiselev E, Marchand C, Zeleznik O, Agama K, Pommier Y, Cushman M.

J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.

PMID:
28418653
33.

The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C).

Tsuda M, Terada K, Ooka M, Kobayashi K, Sasanuma H, Fujisawa R, Tsurimoto T, Yamamoto J, Iwai S, Kadoda K, Akagawa R, Huang SN, Pommier Y, Sale JE, Takeda S, Hirota K.

Oncotarget. 2017 May 16;8(20):33457-33474. doi: 10.18632/oncotarget.16508.

34.

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT.

Nat Med. 2017 Apr;23(4):461-471. doi: 10.1038/nm.4291. Epub 2017 Feb 27.

35.

Temozolomide in the Era of Precision Medicine.

Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y.

Cancer Res. 2017 Feb 15;77(4):823-826. doi: 10.1158/0008-5472.CAN-16-2983. Epub 2017 Feb 3. Review.

36.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

37.

Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks.

Huang SN, Williams JS, Arana ME, Kunkel TA, Pommier Y.

EMBO J. 2017 Feb 1;36(3):361-373. doi: 10.15252/embj.201592426. Epub 2016 Dec 8.

38.

The NCI-60 Methylome and Its Integration into CellMiner.

Reinhold WC, Varma S, Sunshine M, Rajapakse V, Luna A, Kohn KW, Stevenson H, Wang Y, Heyn H, Nogales V, Moran S, Goldstein DJ, Doroshow JH, Meltzer PS, Esteller M, Pommier Y.

Cancer Res. 2017 Feb 1;77(3):601-612. doi: 10.1158/0008-5472.CAN-16-0655. Epub 2016 Dec 6.

39.

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.

Pommier Y, O'Connor MJ, de Bono J.

Sci Transl Med. 2016 Oct 26;8(362):362ps17. Erratum in: Sci Transl Med. 2016 Dec 7;8(368):368er7.

PMID:
27797957
40.

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.

Pommier Y, Sun Y, Huang SN, Nitiss JL.

Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721. doi: 10.1038/nrm.2016.111. Epub 2016 Sep 21. Review.

PMID:
27649880
41.

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y.

Oncotarget. 2016 Nov 22;7(47):76534-76550. doi: 10.18632/oncotarget.12266.

42.

Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.

Riddell IA, Agama K, Park GY, Pommier Y, Lippard SJ.

ACS Chem Biol. 2016 Nov 18;11(11):2996-3001. Epub 2016 Oct 6.

43.

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Guéret M.

Clin Cancer Res. 2017 Apr 15;23(8):2116-2126. doi: 10.1158/1078-0432.CCR-16-0626. Epub 2016 Sep 6.

44.

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

Jdey W, Thierry S, Russo C, Devun F, Al Abo M, Noguiez-Hellin P, Sun JS, Barillot E, Zinovyev A, Kuperstein I, Pommier Y, Dutreix M.

Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. doi: 10.1158/1078-0432.CCR-16-1193. Epub 2016 Aug 24.

45.

Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage.

Rao T, Gao R, Takada S, Al Abo M, Chen X, Walters KJ, Pommier Y, Aihara H.

Nucleic Acids Res. 2016 Dec 1;44(21):10201-10215. Epub 2016 Aug 19.

46.

Small cell lung cancer: Time to revisit DNA-damaging chemotherapy.

Thomas A, Pommier Y.

Sci Transl Med. 2016 Jul 6;8(346):346fs12. doi: 10.1126/scitranslmed.aaf6282. Review.

PMID:
27384345
47.

Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y.

Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1.

48.

F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death.

Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J.

Future Oncol. 2016 Oct;12(19):2183-8. doi: 10.2217/fon-2016-0127. Epub 2016 Jun 22. Review. No abstract available.

49.

Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft.

Kossmann BR, Abdelmalak M, Lopez S, Tender G, Yan C, Pommier Y, Marchand C, Ivanov I.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3232-3236. doi: 10.1016/j.bmcl.2016.05.065. Epub 2016 May 24.

50.

Parallel analysis of ribonucleotide-dependent deletions produced by yeast Top1 in vitro and in vivo.

Cho JE, Huang SY, Burgers PM, Shuman S, Pommier Y, Jinks-Robertson S.

Nucleic Acids Res. 2016 Sep 19;44(16):7714-21. doi: 10.1093/nar/gkw495. Epub 2016 Jun 1.

Supplemental Content

Loading ...
Support Center